r-n-jРоссийский неврологический журналRussian neurological journal2658-79472686-7192МИА10.30629/2658-7947-2022-27-4-55-61r-n-j-336Research ArticleИССЛЕДОВАНИЯ И КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL RESEARCHES AND CASE REPORTSЧастота возникновения и клинические характеристики головной боли при применении гранулоцитарного колониестимулирующего фактора у доноров костного мозга и пациентов с онкогематологическими заболеваниямиHeadache in bone marrow donors and oncohematological patients, who taking granulocyte colony-stimulating factor: incidence and clinical featureshttps://orcid.org/0000-0003-1955-1032СкибаЯ. Б.SkibaIa. B.

Скиба Ярослав Богданович

Санкт-Петербург

Saint Petersburg

yaver-99@mail.ruhttps://orcid.org/0000-0002-6141-486XСоколовА. Ю.SokolovA. Yu.

Санкт-Петербург

Saint Petersburg

alexey.y.sokolov@gmail.comhttps://orcid.org/0000-0003-4409-9615ВагановаЮ. С.VaganovaYu. S.

Санкт-Петербург

Saint Petersburg

ulianasamul@yandex.ruhttps://orcid.org/0000-0003-4789-7460ГончароваЕ. В.GoncharovaE. V.

Санкт-Петербург

Saint Petersburg

Ek.v.goncharova@gmail.comhttps://orcid.org/0000-0001-8699-2482ПолушинА. Ю.PolushinA. Yu.

Санкт-Петербург

Saint Petersburg

alexpolushin@yandex.ruhttps://orcid.org/0000-0002-0215-4623ВладовскаяМ. Д.VladovskayaM. D.

Санкт-Петербург

Saint Petersburg

vladovskayamd@1spbgmu.ruhttps://orcid.org/0000-0002-9589-4136КулагинА. Д.KulaginA. D.

Санкт-Петербург

Saint Petersburg

kulagingem@rambler.ruПервый Санкт-Петербургский государственный медицинский университет имени академика И.П. ПавловаРоссияPavlov First Saint Petersburg State Medical UniversityRussian FederationПервый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова; Институт физиологии им. И.П. Павлова РАНРоссияPavlov First Saint Petersburg State Medical University; Pavlov Institute of Physiology of the Russian Academy of SciencesRussian Federation2022031020222745561Copyright © Скиба Я.Б., Соколов А.Ю., Ваганова Ю.С., Гончарова Е.В., Полушин А.Ю., Владовская М.Д., Кулагин А.Д., 20222022Скиба Я.Б., Соколов А.Ю., Ваганова Ю.С., Гончарова Е.В., Полушин А.Ю., Владовская М.Д., Кулагин А.Д.Skiba I.B., Sokolov A.Y., Vaganova Y.S., Goncharova E.V., Polushin A.Y., Vladovskaya M.D., Kulagin A.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.r-n-j.com/jour/article/view/336

Цель исследования: определение частоты возникновения и клинических характеристик головной боли (ГБ) при применении гранулоцитарного колониестимулирующего фактора (Г-КСФ) для мобилизации стволовых клеток и лечения нейтропении у доноров и пациентов с онкогематологическими заболеваниями соответственно. Материал и методы. В проспективное наблюдательное неконтролируемое исследование включено 39 участников — 20 доноров костного мозга и 19 пациентов с онкогематологическими заболеваниями. Оценивались частота развития и клинические характеристики ГБ на фоне подкожного введения Г-КСФ (филграстим) в дозировках 5–10 мкг/кг в течение 2–5 дней.Результаты. ГБ чаще возникали у доноров в сравнении с пациентами, страдающими онкогематологическими заболеваниями (78,9% vs 35,0%; р = 0,006). Для групп доноров и пациентов с онкогематологическими заболеваниями значимых различий по времени возникновения ГБ относительно начала терапии Г-КСФ, ее длительности, интенсивности, характера и локализации выявлено не было. Пол, возраст, дозировка Г-КСФ и длительность его применения не были ассоциированы с развитием ГБ как в группе доноров, так и в группе пациентов с онкогематологическими заболеваниями.Заключение. ГБ чаще возникает у доноров, нежели у пациентов с заболеванием онкогематологического профиля. Фенотип ГБ не является специфичным и требует дальнейшего уточнения семиотики.

The aim of the study was to assess the incidence and clinical features of headache associated with the use of granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization or neutropenia treatment among oncohematological patients and bone marrow donors.Material and methods. A prospective observational uncontrolled study included 39 participants: 20 bone marrow donors (group 1) and 19 oncohematological patients (group 2). We evaluated the incidence and clinical features of headache after subcutaneous administration of G-CSF (filgrastim) at doses of 5 to 10 μg/kg for 2 to 5 days.Results. Headache occurred in bone marrow donors more often compared to patients with hematological malignancies (78.9% vs 35.0%; p = 0.006). There were no significant differences in the time of headache onset, its duration, intensity, features, and localization between two groups. Gender, age, dose of G-CSF, and duration of its use were not associated with headache development in both groups.Conclusion. Headache occurs more often in bone marrow donors than in patients with hematological malignancies. The phenotype of headache associated with G-CSF exposure is not drug-specific and requires further studies on its semiotics.

гранулоцитарный колониестимулирующий факторголовная больмигреньлимфомамножественная миеломатрансплантация гемопоэтических стволовых клетокдонор костного мозгаgranulocyte colony-stimulating factorheadachemigrainelymphomamultiple myelomahematopoietic stem cell transplantbone marrow donorReferencesKaragiannidis I., Salataj E., Said Abu Egal E., Beswick E.J. G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation. Cytokine. 2021;142:155479. https://doi.org/10.1016/j.cyto.2021.155479Karagiannidis I., Salataj E., Said Abu Egal E., Beswick E.J. G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation. Cytokine. 2021;142:155479. https://doi.org/10.1016/j.cyto.2021.155479Schmitt M., Hoffmann J.M., Lorenz K., Publicover A., Schmitt A., Nagler A. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF. Vox Sang. 2016;111(2):178–186. https://doi.org/10.1111/vox.12397Schmitt M., Hoffmann J.M., Lorenz K., Publicover A., Schmitt A., Nagler A. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF. Vox Sang. 2016;111(2):178–186. https://doi.org/10.1111/vox.12397Brockmann F., Kramer M., Bornhäuser M., Ehninger G., Hölig K. Efficacy and side effects of granulocyte collection in healthy donors. Transfus Med Hemother. 2013;40(4):258–264. https://doi.org/10.1159/000354093Brockmann F., Kramer M., Bornhäuser M., Ehninger G., Hölig K. Efficacy and side effects of granulocyte collection in healthy donors. Transfus Med Hemother. 2013;40(4):258–264. https://doi.org/10.1159/000354093Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4741199ef54f-4bcb-8798d0cc3095f783&t=%20(accessed%20Apr.%2009,%202021Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4741199ef54f-4bcb-8798d0cc3095f783&t=%20(accessed%20Apr.%2009,%202021Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://doi.org/10.1177/0333102417738202Moog R. Donor tolerance and results of stimulation with G-CSF alone or in combination with dexamethasone for the collection of granulocytes. J Clin Apher. 2004;19(3):115–118. https://doi.org/10.1002/jca.20013Moog R. Donor tolerance and results of stimulation with G-CSF alone or in combination with dexamethasone for the collection of granulocytes. J Clin Apher. 2004;19(3):115–118. https://doi.org/10.1002/jca.20013Kröger N., Renges H., Sonnenberg S., Krüger W., Gutensohn K., Dielschneider T. et al. Stem cell mobilisation with 16 microg/ kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant. 2002;29(9):727–730. https://doi.org/10.1038/sj.bmt.1703509Kröger N., Renges H., Sonnenberg S., Krüger W., Gutensohn K., Dielschneider T. et al. Stem cell mobilisation with 16 microg/ kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant. 2002;29(9):727–730. https://doi.org/10.1038/sj.bmt.1703509Reik R.A., Noto T.A., Fernandez H.F. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher. 1997;12(1):10–13. https://doi.org/10.1002/(sici)1098-1101(1997)12:1<10::aid-jca3>3.0.co;2-dReik R.A., Noto T.A., Fernandez H.F. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher. 1997;12(1):10–13. https://doi.org/10.1002/(sici)1098-1101(1997)12:1<10::aid-jca3>3.0.co;2-dCesaro S., Marson P., Gazzola M.V., De Silvestro G., Destro R., Pillon M. et al. The use of cytokine-stimulated healthy donors in allogeneic stem cell transplantation. Haematologica. 2002;87(8 Suppl):35–41.Cesaro S., Marson P., Gazzola M.V., De Silvestro G., Destro R., Pillon M. et al. The use of cytokine-stimulated healthy donors in allogeneic stem cell transplantation. Haematologica. 2002;87(8 Suppl):35–41.Kröger N., Zander A.R. Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma. 2002;43(7):1391–1394. https://doi.org/10.1080/10428190290033323Kröger N., Zander A.R. Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma. 2002;43(7):1391–1394. https://doi.org/10.1080/10428190290033323Kröger N., Renges H., Krüger W., Gutensohn K., Löliger C., Carrero I. et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. British journal of haematology. 2000:111(3);761–765.Kröger N., Renges H., Krüger W., Gutensohn K., Löliger C., Carrero I. et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. British journal of haematology. 2000:111(3);761–765.Nakamura J., Nishi T.M., Yamashita S., Nakamura H., Sato K., Oda Y. et al. Pegfilgrastim-associated large-vessel vasculitis developed during adjuvant chemotherapy for breast cancer: A case report and review of the literature. J Oncol Pharm Pract. 2020;26(7):1785–1790. https://doi.org/10.1177/1078155220910800Nakamura J., Nishi T.M., Yamashita S., Nakamura H., Sato K., Oda Y. et al. Pegfilgrastim-associated large-vessel vasculitis developed during adjuvant chemotherapy for breast cancer: A case report and review of the literature. J Oncol Pharm Pract. 2020;26(7):1785–1790. https://doi.org/10.1177/1078155220910800Gong Y., Hoover-Plow J. The plasminogen system in regulating stem cell mobilization. J Biomed Biotechnol. 2012;2012:437920. https://doi.org/10.1155/2012/437920Gong Y., Hoover-Plow J. The plasminogen system in regulating stem cell mobilization. J Biomed Biotechnol. 2012;2012:437920. https://doi.org/10.1155/2012/437920Goadsby P.J., Holland P.R., Martins-Oliveira M., Hoffmann J., Schankin C., Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553–622. https://doi.org/10.1152/physrev.00034.2015Goadsby P.J., Holland P.R., Martins-Oliveira M., Hoffmann J., Schankin C., Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553–622. https://doi.org/10.1152/physrev.00034.2015Noseda R., Copenhagen D., Burstein R. Current understanding of photophobia, visual networks and headaches. Cephalalgia. 2019;39(13):1623–1634. https://doi.org/10.1177/0333102418784750Noseda R., Copenhagen D., Burstein R. Current understanding of photophobia, visual networks and headaches. Cephalalgia. 2019;39(13):1623–1634. https://doi.org/10.1177/0333102418784750Burstein R., Noseda R., Fulton A.B. Neurobiology of Photophobia. J Neuroophthalmol. 2019;39(1):94–102. https://doi.org/10.1097/WNO.0000000000000766Burstein R., Noseda R., Fulton A.B. Neurobiology of Photophobia. J Neuroophthalmol. 2019;39(1):94–102. https://doi.org/10.1097/WNO.0000000000000766Young N.P., Elrashidi M.Y., McKie P.M., Ebbert J.O. Neuroimaging utilization and findings in headache outpatients: Significance of red and yellow flags. Cephalalgia. 2018;38(12):1841–1848. https://doi.org/10.1177/0333102418758282Young N.P., Elrashidi M.Y., McKie P.M., Ebbert J.O. Neuroimaging utilization and findings in headache outpatients: Significance of red and yellow flags. Cephalalgia. 2018;38(12):1841–1848. https://doi.org/10.1177/0333102418758282Singh N.N., Sahota P. Sleep-related headache and its management. Curr Treat Options Neurol. 2013;15(6):704–722. https://doi.org/10.1007/s11940-013-0258-1Singh N.N., Sahota P. Sleep-related headache and its management. Curr Treat Options Neurol. 2013;15(6):704–722. https://doi.org/10.1007/s11940-013-0258-1Ahn A.H. Southern Headache Society supplement: the neurobiology of throbbing pain in migraine. Headache. 2012;52(Suppl.1):12–14. https://doi.org/10.1111/j.1526-4610.2012.02136.xAhn A.H. Southern Headache Society supplement: the neurobiology of throbbing pain in migraine. Headache. 2012;52(Suppl.1):12–14. https://doi.org/10.1111/j.1526-4610.2012.02136.xMeseeha M.G., Attia M. Throbbing headache is not always migraine; it can be serious. J Community Hosp Intern Med Perspect. 2016;6(5):32361. Published 2016 Oct 26. https://doi.org/10.3402/jchimp.v6.32361Meseeha M.G., Attia M. Throbbing headache is not always migraine; it can be serious. J Community Hosp Intern Med Perspect. 2016;6(5):32361. Published 2016 Oct 26. https://doi.org/10.3402/jchimp.v6.32361Brusadelli T., Carnovale C., Gentili M., Borsadoli C., Speziali A., Perrone V. et al. Throbbing headache associated with enoxaparin administration: a case report, a review of pharmacovigilance databases for similar cases and possible mechanisms. J Clin Pharm Ther. 2015;40(3):342–344. https://doi.org/10.1111/jcpt.12257Brusadelli T., Carnovale C., Gentili M., Borsadoli C., Speziali A., Perrone V. et al. Throbbing headache associated with enoxaparin administration: a case report, a review of pharmacovigilance databases for similar cases and possible mechanisms. J Clin Pharm Ther. 2015;40(3):342–344. https://doi.org/10.1111/jcpt.12257Eyles J.L., Roberts A.W., Metcalf D., Wicks I.P. Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006;2(9):500–510. https://doi.org/10.1038/ncprheum0291Eyles J.L., Roberts A.W., Metcalf D., Wicks I.P. Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol. 2006;2(9):500–510. https://doi.org/10.1038/ncprheum0291Castellani S., D’Oria S., Diana A., Polizzi A.M., Di Gioia S., Mariggiò M.A. et al. G-CSF and GM-CSF Modify Neutrophil Functions at Concentrations found in Cystic Fibrosis. Sci Rep. 2019;9(1):12937. Published 2019 Sep 10. https://doi.org/10.1038/s41598-019-49419-zCastellani S., D’Oria S., Diana A., Polizzi A.M., Di Gioia S., Mariggiò M.A. et al. G-CSF and GM-CSF Modify Neutrophil Functions at Concentrations found in Cystic Fibrosis. Sci Rep. 2019;9(1):12937. Published 2019 Sep 10. https://doi.org/10.1038/s41598-019-49419-zMcColl S.R., Paquin R., Ménard C., Beaulieu A.D. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colonystimulating factor and tumor necrosis factor alpha. J Exp Med. 1992;176(2):593–598. https://doi.org/10.1084/jem.176.2.593McColl S.R., Paquin R., Ménard C., Beaulieu A.D. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colonystimulating factor and tumor necrosis factor alpha. J Exp Med. 1992;176(2):593–598. https://doi.org/10.1084/jem.176.2.593Rambe A.S., Sjahrir H., Machfoed M.H. Tumour Necrosis Factor-Α, Interleukin-1 and Interleukin-6 Serum Levels and Its Correlation with Pain Severity in Chronic Tension-Type Headache Patients: Analysing Effect of Dexketoprofen Administration. Open Access Maced J Med Sci. 2017;5(1):54–57. https://doi.org/10.3889/oamjms.2017.024Rambe A.S., Sjahrir H., Machfoed M.H. Tumour Necrosis Factor-Α, Interleukin-1 and Interleukin-6 Serum Levels and Its Correlation with Pain Severity in Chronic Tension-Type Headache Patients: Analysing Effect of Dexketoprofen Administration. Open Access Maced J Med Sci. 2017;5(1):54–57. https://doi.org/10.3889/oamjms.2017.024Koçer A., Memişoğullari R., Domaç F.M., Ilhan A., Koçer E., Okuyucu S. et al. IL-6 levels in migraine patients receiving topiramate. Pain Pract. 2009;9(5):375–379. https://doi.org/10.1111/j.1533-2500.2009.00301.xKoçer A., Memişoğullari R., Domaç F.M., Ilhan A., Koçer E., Okuyucu S. et al. IL-6 levels in migraine patients receiving topiramate. Pain Pract. 2009;9(5):375–379. https://doi.org/10.1111/j.1533-2500.2009.00301.xConti P., D’Ovidio C., Conti C., Gallenga C.E., Lauritano D., Caraffa A. et al. Progression in migraine: Role of mast cells and proinflammatory and anti-inflammatory cytokines. Eur J Pharmacol. 2019;844:87–94. https://doi.org/10.1016/j.ejphar.2018.12.004Conti P., D’Ovidio C., Conti C., Gallenga C.E., Lauritano D., Caraffa A. et al. Progression in migraine: Role of mast cells and proinflammatory and anti-inflammatory cytokines. Eur J Pharmacol. 2019;844:87–94. https://doi.org/10.1016/j.ejphar.2018.12.004Han D. Association of Serum Levels of Calcitonin Gene-related Peptide and Cytokines during Migraine Attacks. Ann Indian Acad Neurol. 2019;22(3):277–281. https://doi.org/10.4103/aian.AIAN_371_18Han D. Association of Serum Levels of Calcitonin Gene-related Peptide and Cytokines during Migraine Attacks. Ann Indian Acad Neurol. 2019;22(3):277–281. https://doi.org/10.4103/aian.AIAN_371_18Messlinger K., Russo A.F. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia. 2019;39(13):1661–1674. https://doi.org/10.1177/0333102418786261Messlinger K., Russo A.F. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia. 2019;39(13):1661–1674. https://doi.org/10.1177/0333102418786261Gong Q., Lin Y., Lu Z., Xiao Z. Microglia-Astrocyte Cross Talk through IL-18/IL-18R Signaling Modulates Migrainelike Behavior in Experimental Models of Migraine. Neuroscience. 2020;451:207–215. https://doi.org/10.1016/j.neuroscience.2020.10.019Gong Q., Lin Y., Lu Z., Xiao Z. Microglia-Astrocyte Cross Talk through IL-18/IL-18R Signaling Modulates Migrainelike Behavior in Experimental Models of Migraine. Neuroscience. 2020;451:207–215. https://doi.org/10.1016/j.neuroscience.2020.10.019He W., Long T., Pan Q., Zhang S., Zhang Y., Zhang D. et al. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model. J Neuroinflammation. 2019;16(1):78. Published 2019 Apr 10. https://doi.org/10.1186/s12974-019-1459-7He W., Long T., Pan Q., Zhang S., Zhang Y., Zhang D. et al. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model. J Neuroinflammation. 2019;16(1):78. Published 2019 Apr 10. https://doi.org/10.1186/s12974-019-1459-7Zhang X.C., Kainz V., Burstein R., Levy D. Tumor necrosis factor-α induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain. 2011;152(1):140–149. https://doi.org/10.1016/j.pain.2010.10.002Zhang X.C., Kainz V., Burstein R., Levy D. Tumor necrosis factor-α induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain. 2011;152(1):140–149. https://doi.org/10.1016/j.pain.2010.10.002Bowen E.J., Schmidt T.W., Firm C.S, Russo A.F, Durham P.L. Tumor necrosis factor-alpha stimulation of calcitonin generelated peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem. 2006;96(1):65–77. https://doi.org/10.1111/j.1471-4159.2005.03524.xBowen E.J., Schmidt T.W., Firm C.S, Russo A.F, Durham P.L. Tumor necrosis factor-alpha stimulation of calcitonin generelated peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem. 2006;96(1):65–77. https://doi.org/10.1111/j.1471-4159.2005.03524.xYan J., Melemedjian O.K., Price T.J., Dussor G. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol Pain. 2012;8:6. Published 2012 Jan 24. https://doi.org/10.1186/1744-8069-8-6Yan J., Melemedjian O.K., Price T.J., Dussor G. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol Pain. 2012;8:6. Published 2012 Jan 24. https://doi.org/10.1186/1744-8069-8-6

The authors declare that there are no conflicts of interest present.